Search results for "CARRIERS"

showing 10 items of 391 documents

Correction:Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrom…

2020

Lynch syndrome (LS) results from pathogenic variants in the mismatch repair (MMR) genes and is the most common hereditary cancer syndrome, affecting an estimated 1 in 300 individuals. Pathogenic variants in each of the MMR genes path_MLH1, path_MSH2, path_MSH6, and path_PMS2 result in different risks for cancers in organs including the colorectum, endometrium, ovaries, stomach, small bowel, bile duct, pancreas, and upper urinary tract. Accurate estimates of these risks are essential for planning appropriate approaches to the prevention or early diagnosis of cancers but the robustness of previous studies has been limited by factors including retrospective design,1,2 lack of validation in ind…

OncologyMaleColorectal cancer*Lynch syndromePenetranceDNA Mismatch Repair0302 clinical medicineDatabases GeneticMalalties hereditàriesProspective StudiesCàncer*PMS2Genetics (clinical)Mismatch Repair Endonuclease PMS2Cancer0303 health sciencesSex CharacteristicsFactors de risc en les malalties1184 Genetics developmental biology physiologyMLH1Middle Aged16. Peace & justiceLynch syndrome3. Good healthDNA-Binding ProteinsMutS Homolog 2 Proteinsyöpägeenit*MSH2030220 oncology & carcinogenesis*MSH6030211 gastroenterology & hepatologyDNA mismatch repairFemalegeneettiset tekijätMutL Protein Homolog 1Genetic diseasesAdultmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRisk factors in diseasessuolistosyövätMUTATION CARRIERSMLH1Risk AssessmentArticlesukupuoliAge and gender03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseLynchin oireyhtymäGene030304 developmental biologyAgedbusiness.industryEndometrial cancerCorrectionnutritional and metabolic diseasesCancer*MLH1MSH6medicine.diseaseColorectal Neoplasms Hereditary NonpolyposisSurvival Analysisdigestive system diseasesMSH2MSH6Lynch syndromePMS2MSH2Mutation3111 BiomedicineikäbusinessOvarian cancer
researchProduct

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

2014

none 29 no Background: Aim was to select naïve patients with genotype 1 chronic hepatitis C having a high probability of response to Peg-interferon. +. ribavirin therapy. Methods: In 1073 patients (derivation cohort), predictors of rapid and sustained virological response were identified by logistic analysis; regression coefficients were used to generate prediction models for sustained virological response. Probabilities at baseline and treatment week 4 were utilized to develop a decision rule to select patients with high likelihood of response. The model was then validated in 423 patients (validation cohort). Results: In the derivation cohort, 257 achieved rapid virological response and 8…

OncologyMaleHepacivirusPredictive Value of Testchronic hepatitis C; prediction model of response; peginterferon plus ribavirin dual therapyHepacivirusPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundGenotypeViralChronicRapid virological responseDrug CarrierChronic hepatitisSettore MED/12 - GastroenterologiaDrug CarriersbiologyGastroenterologyRecombinant ProteinMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsHCV infectionTreatment OutcomePredictive value of testsCombinationRNA ViralDrug Therapy CombinationFemaleChronic hepatitis; HCV infection; Peg-interferon and ribavirin treatment; Predictors of sustained virological response rapid virological response; Adult; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; RNA Viral; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Hepatology; GastroenterologyViral loadHumanAdultmedicine.medical_specialtyGenotypePrognosiAlpha interferonPredictors of sustained virological response rapid virological responseReal-Time Polymerase Chain ReactionAntiviral AgentsDrug TherapyPredictive Value of TestsInternal medicinePredictors of sustained virological responseLinear regressionRibavirinmedicinechronic hepatitis CHumansAntiviral AgentHCV infection; Predictors of sustained virological response Rapid virological response; Peg-interferon and ribavirin treatment; Chronic hepatitisHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C Chronicbiology.organism_classificationchemistryImmunologyChronic hepatitiRNAprediction model of responsepeginterferon plus ribavirin dual therapybusinessPeg-interferon and ribavirin treatmentDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association…

2013

AbstractThe first-generation Protease Inhibitors Boceprevir and Telaprevir administered in triple therapy regimens with Peg-interferon alpha and Ribavirin have been proven effective in increasing the rate of Sustained Virological Response in both naive and treatment-experienced patients with chronic genotype-1 hepatitis C. However, at the individual level, the therapeutic advantage of triple therapy is highly variable and results from the combination of multiple factors related to the characteristics of patient, viral status and liver disease.The recommendations presented are promoted by the Italian Association for the Study of the Liver, with the aim to help the physician in the decision-m…

Oncologymedicine.medical_specialtyProlinePegylated-interferonAlpha interferonHepacivirusPharmacologyAntiviral AgentsTelaprevirTelaprevirPolyethylene GlycolsHCV THERAPYchemistry.chemical_compoundLiver diseaseDrug TherapyPegylated interferonBoceprevirInternal medicineRibavirinmedicineHumansProtease InhibitorsChronicBoceprevir; Cirrhosis; Hepatitis C; Pegylated-interferon; Ribavirin; Telaprevir; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Gastroenterology; HepatologyBoceprevirDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis CHepatologyHepatitis C Chronicmedicine.diseaseHepatitis CCirrhosischemistryCombinationDrug Therapy CombinationbusinessOligopeptidesmedicine.drug
researchProduct

Cellular Uptake of siRNA-Loaded Nanocarriers to Knockdown PD-L1: Strategies to Improve T-cell Functions

2020

T-cells are a type of lymphocyte (a subtype of white blood cells) that play a central role in cell-mediated immunity. Currently, adoptive T-cell immunotherapy is being developed to destroy cancer cells. In this therapy, T-cells are harvested from a patient&rsquo

PD-L1Small interfering RNAT-LymphocytesLymphocytemedicine.medical_treatmentT cellImmunotherapy AdoptiveB7-H1 AntigenArticlemedicineHumansNanotechnologyRNA Small Interferinglcsh:QH301-705.5Gene knockdownnanocarriersChemistryT-cellsCancercellular uptakeGeneral MedicineImmunotherapymedicine.diseasemedicine.anatomical_structurelcsh:Biology (General)siRNACancer cellCancer researchNanocarriersadoptive immunotherapyCells
researchProduct

Lipid nanoparticles as delivery vehicles for the Parietaria judaica major allergen Par j 2

2011

Maria Luisa Bondì1,*, Giovanna Montana2,*, Emanuela Fabiola Craparo3, Roberto Di Gesù3, Gaetano Giammona3, Angela Bonura2, Paolo Colombo21Istituto per lo Studio dei Materiali Nanostrutturati, 2Istituto di Biomedicina ed Immunologia Molecolare, Consiglio Nazionale delle Ricerche, 3Laboratory of Biocompatible Polymers, Dipartimento di Scienze e Tecnologie Molecolari e Biomolecolari Stembio, Università di Palermo, Palermo, Italy *These authors contributed equally to this workAbstract: Parietaria pollen is one of the major causes of allergic reaction in southern Europe, affecting about 30% of all allergic patients in this area. Specific immunotherapy is the only…

ParietariaMembrane lipidsBiophysicsPharmaceutical Sciencerecombinant allergensEnzyme-Linked Immunosorbent AssayBioengineeringmedicine.disease_causelaw.inventionBiomaterialsMembrane LipidsAllergenlawInternational Journal of NanomedicineParietaria judaica (Par j)Drug DiscoverySolid lipid nanoparticlemedicineHumansParticle SizePyrophosphatasesOriginal ResearchPlant ProteinsDrug Carriersallergic rhinitisbiologyPhosphoric Diester HydrolasesChemistryOrganic ChemistryRhinitis Allergic SeasonalGeneral MedicineAllergensbiology.organism_classificationMolecular biologyRecombinant ProteinsBasophilssolid lipid nanoparticlesBiochemistrySettore CHIM/09 - Farmaceutico Tecnologico Applicativodrug deliveryDrug deliveryParietaria judaicaRecombinant DNAsolid lipid nanoparticles Parietaria judaica (Par j) drug delivery recombinant allergens specific immunotherapy allergic rhinitis.NanoparticlesEmulsionsImmunotherapyDrug carrierspecific immunotherapyInternational Journal of Nanomedicine
researchProduct

Functional Magnetic Mesoporous Silica Microparticles Capped with an Azo-Derivative: A Promising Colon Drug Delivery Device

2018

[EN] Magnetic micro-sized mesoporous silica particles were used for the preparation of a gated material able to release an entrapped cargo in the presence of an azo-reducing agent and, to some extent, at acidic pH. The magnetic mesoporous microparticles were loaded with safranin O and the external surface was functionalized with an azo derivative 1 (bearing a carbamate linkage) yielding solid S1. Aqueous suspensions of S1 at pH 7.4 showed negligible safranin O release due to the presence of the bulky azo derivative attached onto the external surface of the inorganic scaffold. However, in the presence of sodium dithionite (azoreductive agent), a remarkable safranin O delivery was observed. A…

Pharmaceutical Science02 engineering and technologyFerric Compounds01 natural sciencesazo reductorcolon releaseAnalytical ChemistrySodium dithionitechemistry.chemical_compoundQUIMICA ORGANICADrug DiscoveryMoietymagnetic mesoporous silicaDrug CarriersAqueous solutionHydrolysisHydrogen-Ion ConcentrationSilicon Dioxide021001 nanoscience & nanotechnologyControlled releaseMicrospheresChemistry (miscellaneous)Drug deliveryMolecular Medicine0210 nano-technologyOxidation-ReductionPorosityColonSurface Properties010402 general chemistryArticleMagneticsChloridesSafraninQUIMICA ANALITICAHumansFerrous CompoundsPhysical and Theoretical Chemistrymagnetic mesoporous silica; azo derivatives; pH triggered; azo reductor; colon releaseQUIMICA INORGANICAOrganic ChemistryDithioniteMesoporous silica0104 chemical sciencesDrug LiberationchemistryNanoparticlesPhenazinespH triggeredMesoporous materialAzo Compoundsazo derivativesNuclear chemistryMolecules; Volume 23; Issue 2; Pages: 375
researchProduct

Propolis-Based Nanofiber Patches to Repair Corneal Microbial Keratitis

2021

In this research, polyvinyl-alcohol (PVA)/gelatin (GEL)/propolis (Ps) biocompatible nanofiber patches were fabricated via electrospinning technique. The controlled release of Propolis, surface wettability behaviors, antimicrobial activities against the S. aureus and P. aeruginosa, and biocompatibility properties with the mesenchymal stem cells (MSCs) were investigated in detail. By adding 0.5, 1, and 3 wt.% GEL into the 13 wt.% PVA, the morphological and mechanical results suggested that 13 wt.% PVA/0.5 wt.% GEL patch can be an ideal matrix for 3 and 5 wt.% propolis addition. Morphological results revealed that the diameters of the electrospun nanofiber patches were increased with GEL (from…

Pharmaceutical ScienceBiocompatible Materials02 engineering and technologyGelatinAnalytical ChemistryContact angleQD241-4410302 clinical medicineAnti-Infective AgentsSpectroscopy Fourier Transform InfraredDrug DiscoveryMesenchymal stem cell proliferationDrug CarriersChemistrySSCAFFOLDHYDROGELP<i>S. aureus</i>021001 nanoscience & nanotechnologyControlled releaseaeruginosaElectrospinningpropolisChemistry (miscellaneous)microbial keratitisPseudomonas aeruginosaBLINDNESSMolecular MedicineELECTROSPUN0210 nano-technologyStaphylococcus aureusfood.ingredient<i>P. aeruginosa</i>BiocompatibilitySurface PropertiesFABRICATIONMicrobial Sensitivity TestsCHEMICAL-COMPOSITIONaureusArticle03 medical and health sciencesfoodnanofibersPhysical and Theoretical Chemistrycorneal patchelectrospinningKeratitisCOMPOSITEGELATINOrganic ChemistryPropolisS. aureusDrug LiberationP. aeruginosaPolyvinyl AlcoholNanofiber030221 ophthalmology & optometryPROPERTYMEMBRANENuclear chemistry
researchProduct

Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η5-C5H5)(PPh3)2]+ as Promising Drugs Against Cisplatin-Resistant Ca…

2018

Here and for the first time, we show that the organometallic compound [Ru(&eta

Pharmaceutical Sciencecisplatin01 natural sciencesAnalytical ChemistrydendrimersCoordination ComplexesDrug DiscoveryMoietyplatinummetallitta116Molecular StructureChemistrymolekyylitnanomedicineNanomedicineChemistry (miscellaneous)MCF-7 CellsMolecular MedicineplatinaDendrimersEpithelial-Mesenchymal TransitionCell SurvivalAntineoplastic Agents.myrkyllisyys010402 general chemistryArticlecancer treatmentlcsh:QD241-441Faculdade de Ciências Exatas e da Engenharialcsh:Organic chemistryDendrimerCell Line TumorOrganometallic CompoundsHumansPhysical and Theoretical ChemistryrutheniumPlatinumCell ProliferationTumor microenvironmentCancer och onkologiToxicitynanocarrierssyöpähoidot010405 organic chemistryOrganic ChemistryMesenchymal stem celltoxicityMesenchymal Stem CellsCombinatorial chemistrykantasolutnanolääketiede0104 chemical scienceslääkkeetTumor progressionCell cultureDrug Resistance NeoplasmmetallodrugsCancer and OncologyCancer cellNanocarriersCaco-2 CellsDrug Screening Assays Antitumor<i>cisplatin</i>hMSCs
researchProduct

Core-shell functionalized zirconium-pemetrexed coordination nanoparticles as carriers with a high drug content

2019

Selected drug molecules with Lewis base functions can be assembled into coordinative nanoparticles (NPs) by linking them with suitable metal ions. Such nanomaterials exhibit a high material economy due to high drug contents and minor amounts of inactive additives. The antifolate pemetrexed (PMX) which is used for the treatment of lung cancers contains two carboxy functions that are able to undergo coordinative binding of metal ions. This study presents the development of a multilayer PMX NP system where each layer serves a distinct purpose. The metal-drug NP core is assembled in a bottom-up approach by coordinative interactions between zirconium (IV) ions and PMX molecules. Since the NP cor…

PharmacologyChemistryMetal ions in aqueous solutionBiochemistry (medical)Pharmaceutical ScienceMedicine (miscellaneous)NanoparticleCombinatorial chemistryNanomaterialsDrug deliveryClick chemistryMoleculePharmacology (medical)Lewis acids and basesNanocarriersGenetics (clinical)
researchProduct

Therapeutic and diagnostic applications of nanoparticles.

2011

Nanoparticles are sphere-like biocompatible materials made of inert silica, metal or crystals of a few nanometers in size. They are emerging as a novel class of therapeutics for cancer treatment. Being more selective and specific toward their targets, nanoparticles have the ability to enhance the anticancer effects and to simultaneously reduce systemic toxicity compared with conventional therapeutics. Furthermore, they offer the potential to overcome drug resistance leading to higher intracellular drug accumulation. Nowadays, nanotechnologies are applied to molecular diagnostics and incorporated in cutting-edge molecular diagnostic methods, such as DNA and protein microarray biochips. Nanot…

PharmacologyDrug Carriersbusiness.industryClinical BiochemistryMolecular Diagnostic MethodNanoparticleNanotechnologyAntineoplastic AgentsMolecular diagnosticsDrug accumulationBiocompatible materialMicroarray AnalysisDrug Delivery SystemsNanomedicineNeoplasmsDrug DiscoveryDrug deliveryProtein microarrayMolecular MedicineMedicineAnimalsHumansNanoparticlesbusinessBiochipCurrent drug targets
researchProduct